scholarly journals Increased HERV-K(HML-2) Transcript Levels Correlate with Clinical Parameters of Liver Damage in Hepatitis C Patients

Cells ◽  
2021 ◽  
Vol 10 (4) ◽  
pp. 774
Author(s):  
Melanie Weber ◽  
Vidya Padmanabhan Nair ◽  
Tanja Bauer ◽  
Martin F. Sprinzl ◽  
Ulrike Protzer ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Liver Function ◽  
Viral Infections ◽  
Endogenous Retroviruses ◽  
Clinical Parameters ◽  
Transcript Levels ◽  
Direct Acting Antiviral ◽  
Drastic Increase ◽  
Direct Acting ◽  
Therapy Success

Chronic hepatitis C virus (HCV) infection is closely associated with a plethora of diseases, including cancers and autoimmune disorders. However, the distinct triggers and cellular networks leading to such HCV-derived diseases are poorly understood. Around 8% of the human genome consists of human endogenous retroviruses. They are usually silenced but can be reactivated by environmental conditions, including viral infections. Our current understanding indicates that the activation of one specific family—namely, HERV-K(HML-2)—is linked to distinct pathologies, including cancer and autoimmunity. In this study, we analyzed the transcription levels of HERV-K(HML-2) in 42 HCV-infected patients receiving direct-acting antiviral therapies. Samples from the start of treatment until 12 weeks post-treatment were investigated. Our results show increased HERV-K(HML-2) transcript levels in patients with HCV-derived liver cirrhosis throughout the observation period. Several clinical parameters specifying poor liver function are positively correlated with HERV-K(HML-2) expression. Of note, patients without a sustained viral clearance showed a drastic increase in HERV-K(HML-2) transcript levels. Together, our data suggest that increased HERV-K(HML-2) expression is correlated with reduced liver function as well as therapy success in HCV-infected patients.

Changes in liver function and body composition by direct-acting antiviral therapy for hepatitis C virus infection

2017 ◽  
Vol 48 (5) ◽  
pp. 337-344 ◽  
Author(s):  
Ryosuke Sugimoto ◽  
Motoh Iwasa ◽  
Nagisa Hara ◽  
Yasuyuki Tamai ◽  
Kyoko Yoshikawa ◽  
...  
Keyword(s):  
Body Composition ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virus Infection ◽  
Liver Function ◽  
Antiviral Therapy ◽  
Hepatitis C Virus Infection ◽  
Direct Acting Antiviral ◽  
Direct Acting

Time‐dependent improvement of liver inflammation, fibrosis and metabolic liver function after successful direct‐acting antiviral therapy of chronic hepatitis C

2019 ◽  
Vol 27 (1) ◽  
pp. 28-35 ◽  
Author(s):  
Tea Lund Laursen ◽  
Cecilie Brøckner Siggaard ◽  
Konstantin Kazankov ◽  
Thomas Damgaard Sandahl ◽  
Holger Jon Møller ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Liver Function ◽  
Antiviral Therapy ◽  
Chronic Hepatitis C ◽  
Time Dependent ◽  
Liver Inflammation ◽  
Direct Acting Antiviral ◽  
Metabolic Liver Function ◽  
Direct Acting

Pre- and Post-Transplant Treatment of Viral Hepatitis C

2017 ◽  
Vol 35 (4) ◽  
pp. 347-350 ◽  
Author(s):  
David Mutimer
Keyword(s):  
Hepatitis C ◽  
Liver Function ◽  
Liver Failure ◽  
Recurrent Infection ◽  
Liver Function Tests ◽  
Waiting List ◽  
Direct Acting Antiviral ◽  
Compensated Cirrhosis ◽  
Viral Hepatitis C ◽  
Direct Acting

Background: Hepatitis C (HCV) is a common cause of liver failure and liver cancer, and is a frequent indication for liver transplantation (LT). Until recently, a majority of transplanted patients were viraemic at the time of transplantation and they inevitably underwent recurrent infection of the graft. Prior to the availability of specific direct-acting antiviral (DAA) drugs, HCV infection was seldom successfully treated before or after transplantation. Key Messages: During the past 2 years, the use of interferon-free DAA therapy has transformed the management of patients post-LT and of patients on the transplant waiting list. DAA treatment post-LT can eradicate infection and normalize liver function tests in a majority of treated patients. An improvement in long-term graft and patient outcome can be anticipated. DAA treatment of patients with liver failure awaiting LT eliminates infection and is associated with an improvement in the liver function for a majority of treated patients. The majority still require transplantation, though some may improve sufficiently and quickly enough to be removed from the LT waiting list. Conclusions: Eventually, as greater numbers of patients with compensated cirrhosis are successfully treated with DAAs, HCV-associated liver failure may become an uncommon indication for LT.

Su1466 The Beneficial Effects on Liver Function After Administration of a Direct Acting Antiviral Drug Therapy in Chronic Hepatitis C

2016 ◽  
Vol 150 (4) ◽  
pp. S1107
Author(s):  
Yasuhiro Tsuda ◽  
Keisuke Yokohama ◽  
Ken Nakamura ◽  
Hideko Ohama ◽  
Tetsuya Sujishi ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Drug Therapy ◽  
Liver Function ◽  
Chronic Hepatitis C ◽  
Antiviral Drug ◽  
Direct Acting Antiviral ◽  
Beneficial Effects ◽  
Direct Acting
Sign in / Sign up

Export Citation Format

Share Document